Pharmaceutical Business Review

AUGUST 28, 2023

We are excited to leverage our expertise and resources to help develop next-generation booster vaccines that will enhance global immunity and save lives. This award results from our focused investment in countering infectious diseases and further builds upon our growing federally funded clinical trials portfolio.”

Vaccines 52

Vaccines Clinical Pharmacology Immunity Immunization 52

European Pharmaceutical Review

MARCH 11, 2024

For example, broadly neutralising antibodies (bNAbs), capsid inhibitors and maturation inhibitors all might play a role in fighting HIV from the initial binding and fusion of HIV into immune cells, to where it integrates into the cell, out to its assembly and maturation.

Immunity 98

Immunity Immunization Clinical Pharmacology Drug Development 98

pharmaphorum

NOVEMBER 4, 2020

The M&S approach should be integrative, from the molecular level to the clinical and population outcomes. It should be conceived both as a proof of concept tool and a MIDD (Model Informed Drug Development, to use the FDA jargon) tool for potential treatments, including vaccines, and combinations of drugs.

Vaccines 105

Vaccines Clinical Pharmacology Immunity Immunization 105

European Pharmaceutical Review

JULY 13, 2023

1 Europe, however, is well placed to become a leader in driving the clinical translation of medications that display significant promise in laboratory-based studies. 3 With established drug development pathways, we are accustomed to a rigid structure of translation from bench to bedside.

Compounding 98

Compounding Drug Development Clinical Pharmacology Documentation 98